Thomas Cunningham, MD
Internal Medicine · Birmingham, ALNPI 1982191136
Payments from drug & device makers
Across 221 payments — averaging $18.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$607
- Pfizer$423
- Amgen$345
- Abbott$327
- Exact Sciences$303
- Bayer$302
- plus $2K from 22 others
What the payments were for
- Food & beverage$4,129100%
- Entertainment$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 35 | $607 |
| Pfizer | 20 | $423 |
| Amgen | 16 | $345 |
| Abbott | 17 | $327 |
| Exact Sciences | 18 | $303 |
| Bayer | 16 | $302 |
| Dexcom, Inc. | 14 | $261 |
| Novo Nordisk | 13 | $254 |
| AstraZeneca | 9 | $168 |
| AbbVie | 9 | $159 |
| Corcept Therapeutics | 7 | $149 |
| GSK | 9 | $148 |
| Phathom Pharmaceuticals, Inc. | 9 | $145 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $136 |
| Boehringer Ingelheim | 4 | $81 |
| Shield Therapeutics Inc | 3 | $65 |
| Axsome Therapeutics, Inc. | 2 | $55 |
| Merck | 2 | $37 |
| Pulmonx Corporation | 2 | $31 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Boston Scientific | 1 | $18 |
| Antares Pharma, Inc. | 1 | $15 |
| Tolmar, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Optos, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $12 |
How this compares
$4,143 in reported general payments places this provider in the 80th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 83 | $82,673 |
| EliquisApixaban | 72 | $64,724 |
| MounjaroTirzepatide | 57 | $58,945 |
| JanuviaSitagliptin Phosphate | 66 | $49,964 |
| JardianceEmpagliflozin | 26 | $37,221 |
| FarxigaDapagliflozin Propanediol | 25 | $34,273 |
| MyrbetriqMirabegron | 18 | $16,753 |
| GemtesaVibegron | 23 | $13,012 |
| LinzessLinaclotide | 14 | $11,347 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $7,783 |
| Atorvastatin Calcium | 388 | $5,775 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 44 | $4,632 |
| Levemir FlexpenInsulin Detemir | 20 | $4,269 |
| SynthroidLevothyroxine Sodium | 37 | $3,795 |
| Losartan Potassium | 204 | $2,879 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $254 | $82,67383 claims |
| PfizerEliquis | $423 | $64,72472 claims |
| Lilly USA, LLCMounjaro | $607 | $58,94557 claims |
| MerckJanuvia | $37 | $49,96466 claims |
| Boehringer IngelheimJardiance | $81 | $37,22126 claims |
| AstraZenecaFarxiga | $168 | $34,27325 claims |
| AbbVieLinzess, Synthroid | $159 | $15,14351 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $18 | $13,01223 claims |
| GSKBreo Ellipta | $148 | $7,78314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Birmingham
- David DeatkineBirmingham$8M
- James SullivanBirmingham$6M
- Ramy TomaBirmingham$5.1M
- William KirbyBirmingham$2.3M
- Jordan VaughnBirmingham$1.6M
- Stefanie KrickBirmingham$527K
- Ryan WeldonBirmingham$458K
- Ashraf KhanBirmingham$215K
- Robert LewisBirmingham$201K
- David WynneBirmingham$180K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.